Full-Time

Sr Director Market Planning

Fraud & Identity

Confirmed live in the last 24 hours

RELX

RELX

1,001-5,000 employees

Provides analytics and decision tools for professionals

No salary listed

Senior, Expert

London, UK

Candidates should be located in the UK or EU.

Category
Project Management
Strategy Development
Business Development
Business & Strategy
Required Skills
Market Research
Requirements
  • 10+ years of experience with increasing strategy, product and P&L roles with a focus on fraud and identity and a proven track record of leadership and strategic impact.
  • Expert knowledge of fraud and identity regulations throughout EMEA, trends and analytic practices.
  • Proven experience delivering on revenue objectives in a B2B environment, developing and growing new and existing business relationships.
  • Exceptional leadership and people management skills, with a passion for developing and motivating high-performing teams.
  • Strong communication and relationship-building abilities, with the capacity to influence change through collaboration with senior internal and external stakeholders.
  • Strategic thinker with excellent analytical and problem-solving skills, capable of making data-driven decisions to solve complex problems.
  • Bachelor's degree in a relevant field with exceptional academic achievement; master's degree preferred.
  • Significant travel required (up to 25-50%), including global travel.
Responsibilities
  • Accountable for revenue objectives by the EMEA region. Reviews and evaluates Fraud & Identity performance on a continuing basis and establishes the proper measures of performance, inclusive of pricing and margin of services. Provides direction for modification and implementation of contingency plans in accordance with prevailing business conditions as required to maximize regional performance. Develops and recommends sales channel strategy utilizing market research and performance data to drive investment decisions.
  • Directs the development of short- and long-range operating objectives that integrates country-level plans into a cohesive regional strategy to achieve maximum revenue growth for the business and allow us to offer differentiated capabilities that will solve evolving fraud and identity challenges.
  • Stay at the forefront of evolving regional fraud and identity regulations, ensuring our solutions are ahead of the curve and always fully compliant. Provide thought leadership and guidance to internal and external stakeholders on emerging trends and issues.
  • Support relationships with key accounts, industry analysts and associations, public service organizations and vendors as necessary in the overall management of Fraud and Identity in the region.
  • Define our core Fraud and Identity messaging and representation of LexisNexis Risk Solutions as a subject matter expert at industry conferences, seminars, and events. Contribute thought leadership articles, whitepapers, and presentations to elevate our standing in the field.
  • Build and develop talent to achieve business objectives and long-term organization growth. Further a culture of innovation, collaboration and growth by inspiring the organization to achieve our missions.
Desired Qualifications
  • Master's degree preferred.

RELX provides information-based analytics and decision tools tailored for professionals and businesses across various sectors. The company operates in four key areas: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products utilize extensive data and analytics to assist clients, such as researchers, healthcare professionals, legal experts, and business leaders, in making informed decisions and enhancing productivity. RELX primarily uses a subscription model, ensuring a consistent revenue stream, while also earning from transactional sales and advertising. What sets RELX apart from competitors is its commitment to corporate responsibility, focusing on diversity, social justice, and sustainable development, actively supporting the United Nations' Sustainable Development Goals through its offerings.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Simplify Jobs

Simplify's Take

What believers are saying

  • Elsevier's AI framework sets a new standard for responsible AI in healthcare.
  • Embase's expansion enhances evidence-based decision-making in pharmaceuticals and medical devices.
  • ScienceDirect AI significantly reduces research time, supporting better research outcomes.

What critics are saying

  • AI integration in clinical tools may face scrutiny over potential clinical harm.
  • Data management challenges in Embase could slow research and regulatory processes.
  • ScienceDirect AI may encounter issues with research reproducibility and data accuracy.

What makes RELX unique

  • RELX excels in diverse industries with specialized analytics and decision tools.
  • The company's subscription model ensures a steady stream of recurring revenue.
  • RELX's commitment to corporate responsibility aligns with global sustainable development goals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence

PR Newswire
May 6th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World'S Most Comprehensive Biomedical Database

Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safetyLONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface

ACN Newswire
Apr 21st, 2025
Inter Airport Southeast Asia 2025 Sets A New Benchmark For Attendance, Marking Its 8Th Edition In Singapore With Record-Breaking Participation

Trade attendees gathered in anticipation for the opening day of IASEA 2025. SINGAPORE, Apr 21, 2025 - (ACN Newswire) - The 8th edition of inter airport Southeast Asia (IASEA) was held in Singapore from 25-27 March 2025. Spanning across 6,259 sqm of exhibition space, the airport exhibition and conference brought together 3,621 industry trade professionals from 53 countries and regions, and featured 134 exhibiting companies including pavilions representing Germany, Italy, Japan and Singapore. The event saw a 43% increase in exhibitor size and a 15.6% rise in attendee numbers, underscoring the rising significance of IASEA as a platform for productive discussions. The event's achievement is also attributed to the increasing demands of operators and the rapid development and expansion of airports in Asia

PR Newswire
Apr 1st, 2025
Lexisnexis Risk Solutions Expands Leadership Team With Fraud Prevention Expert Glenn Prager

Veteran Fraud Prevention Leader Joins LexisNexis Risk Solutions to Strengthen Program Integrity and Protect Public FundsWASHINGTON, April 1, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions today announced the addition of Glenn Prager as Executive Director of Government Risk Solutions, reinforcing its commitment to safeguarding the integrity of our nation's critical social safety nets. Prager, a proven leader in combating fraud, waste, and abuse, brings over two decades of public and private sector experience leveraging data, analytics, and technology to ensure benefits reach those who truly need them. Glenn will work across key markets, including the U.S. Department of Health and Human Services, State and Local Medicaid Departments, and Inspector General Offices."With today's rapidly evolving fraud landscape, ensuring the integrity of federal and state benefit programs is more critical than ever," said Haywood Talcove, CEO of LexisNexis Risk Solutions – Government. "Glenn Prager's unparalleled expertise in program integrity, forensic auditing, and multi-jurisdictional fraud investigations makes him an invaluable addition to our team. His leadership will strengthen our ability to support government agencies in their mission to protect public funds, while ensuring those in need receive essential services."Prager's career has been defined by his dedication to strengthening government oversight, developing anti-fraud strategies, and enhancing compliance across Medicare, Medicaid, and other federally funded programs